The Food and Drug Administration granted Breakthrough Therapy Designation to Global Blood Therapeutics Inc.'s (Nasdaq: GBT) voxelotor to treat sickle cell disease sending the stock price soaring $7.55 to close at $47.15.
Breakthrough Therapy Designation granted to Global Blood Therapeutics
January 09, 2018 at 17:10 PM EST
